Skaana Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,800
Closed -$18.8K 157
2025
Q4
$18.8K Hold
2,800
0.01% 141
2025
Q3
$24.3K Hold
2,800
0.01% 134
2025
Q2
$17.6K Buy
+2,800
New +$18.5K 0.01% 123
2025
Q1
Sell
-4,900
Closed -$39.4K 150
2024
Q4
$39.4K Hold
4,900
0.01% 121
2024
Q3
$61.9K Sell
4,900
-41,800
-90% -$540K 0.02% 102
2024
Q2
$591K Sell
46,700
-140,100
-75% -$1.41M 0.18% 75
2024
Q1
$166M Buy
186,800
+32,500
+21% +$151K 3.3% 7
2023
Q4
$741K Buy
154,300
+78,000
+102% +$477K 0.13% 68
2023
Q3
$552K Sell
76,300
-2,200
-3% -$17.6K 0.14% 80
2023
Q2
$583K Sell
78,500
-19,100
-20% -$150K 0.13% 80
2023
Q1
$676K Buy
+97,600
New +$898K 0.21% 61

Other funds holding NVAX

Skaana Management's NVAX Position: Q1 2026 in Review

Skaana Management sold out of Novavax (NVAX) in Q1 2026, closing a stake of 68,300 shares — an estimated $459K sold.

Skaana Management first reported a position in NVAX in Q2 2023 and held it in 9 quarters. The position peaked at $4.22M in Q3 2024. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Skaana Management reported no remaining Novavax position as of Q1 2026 after selling out during the quarter.
  • Skaana Management sold 68,300 Novavax shares in Q1 2026, an estimated $459K.
  • Skaana Management first reported a position in Novavax in Q2 2023 and held it in 9 quarters.
  • Skaana Management's Novavax position peaked at $4.22M in Q3 2024.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Skaana Management's 13F filing for Q1 2026, filed 11 May 2026.